



Patent
Attorney's Docket No. 033136-179

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

Anthony E. Bolton, et al.

Application No.: 09/866,488

Filed: May 25, 2001

For: APOPTOTIC ENTITIES FOR USE IN
TREATMENT OF T-CELL-MEDIATED
AND INFLAMMATORY DISORDERS

Group Art Unit: 1642

Examiner: M. Yu

#7
RECEIVED

JUN 12 2002

TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a Supplemental Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ [X] No additional fee for submission of an IDS is required.
- ☐ [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ [] A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

By:

Dawn M. Gardner
Registration No. 44,118

Date: June 10, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Anthony E. Bolton, et al.) Group Art Unit: 1642
)
Application No.: 09/866,488) Examiner: M. Yu
)
Filed: May 25, 2001)
)
For: APOPTOTIC ENTITIES FOR USE IN)
TREATMENT OF T-CELL-MEDIATED)
AND INFLAMMATORY DISORDERS)
)

RECEIVED

JUN 12 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

1. International Publication No. WO 98/07436, published February 26, 1998.
2. Bodey, B., et al. "Apoptosis in the Mammalian Thymus During Normal Histogenesis and Under Various *In Vitro* and *In Vivo* Experimental Conditions," *In Vivo*, 12(1): 123-134 (1998).
3. Shivji, G.M., et al. "The Effect of VAS 972 on Allergic Contact Hypersensitivity," *J. of Cutaneous Medicine and Surgery*, 4(3): 132-137 (2000).
4. Shivji, G.M., et al. "Effects of VAS972 Therapy on Allergic Contact Hypersensitivity," *J. Invest. Dermatology*, 114(4): 862 (2000) (abstract.).


I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

By citing the above references, Applicants do not acquiesce or admit that any of these documents are "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Dawn M. Gardner
Registration No. 44,118

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

Date: June 7, 2002